Skip to content
Acting Auditions – Lifestyle
Author:
ENA Respiratory
ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections
September 15, 2026
ENA Respiratory Awarded Biointelect Venturer Funding to Support New Study in Asthma Patients of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
September 1, 2026
ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations
June 15, 2026
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
May 11, 2026
ENA Respiratory Appoints Melissa Faris to Board
April 23, 2026